tertensif
les laboratoires servier - indapamidas - plėvele dengtos tabletės - 2,5 mg - indapamide
tertensif sr
les laboratoires servier - indapamidas - pailginto atpalaidavimo tabletės - 1,5 mg - indapamide
triplixam
les laboratoires servier - perindoprilio argininas/indapamidas/amlodipinas - plėvele dengtos tabletės - 10 mg/2,5 mg/10 mg; 10 mg/2,5 mg/5 mg; 5 mg/1,25 mg/5 mg; 2,5 mg/0,625 mg/5 mg; 5 mg/1,25 mg/10 mg - perindopril, amlodipine and indapamide
triveram
les laboratoires servier - atorvastatinas/perindoprilio argininas/amlodipinas - plėvele dengtos tabletės - 40 mg/10 mg/10 mg; 20 mg/10 mg/10 mg; 20 mg/10 mg/5 mg; 20 mg/5 mg/5 mg; 10 mg/5 mg/5 mg - atorvastatin, amlodipine and perindopril
viacoram
les laboratoires servier - perindoprilio argininas/amlodipinas - tabletės - 7 mg/5 mg; 3,5 mg/2,5 mg - perindopril and amlodipine
presteram
les laboratoires servier - perindoprilio argininas/amlodipinas - tabletės - 10 mg/10 mg - perindopril and amlodipine
viacoram
les laboratoires servier - perindoprilio argininas/amlodipinas - tabletės - 7 mg/5 mg - perindopril and amlodipine
tibsovo
les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antinavikiniai vaistai - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.
flutensif
les laboratoires servier - indapamidas/amlodipinas - modifikuoto atpalaidavimo tabletės - 1,5 mg/5 mg; 1,5 mg/10 mg - amlodipine and diuretics
valdoxan
les laboratoires servier - agomelatine - depresijos sutrikimas, majoras